144 related articles for article (PubMed ID: 8630922)
1. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate.
Janssen T; Darro F; Petein M; Raviv G; Pasteels JL; Kiss R; Schulman CC
Cancer; 1996 Jan; 77(1):144-9. PubMed ID: 8630922
[TBL] [Abstract][Full Text] [Related]
2. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
3. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
4. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
[TBL] [Abstract][Full Text] [Related]
5. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells.
Yeh JY; Huang WJ; Kan SF; Wang PS
J Urol; 2001 Nov; 166(5):1937-42. PubMed ID: 11586264
[TBL] [Abstract][Full Text] [Related]
7. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
11. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
Gupta S; Ahmad N; Nieminen AL; Mukhtar H
Toxicol Appl Pharmacol; 2000 Apr; 164(1):82-90. PubMed ID: 10739747
[TBL] [Abstract][Full Text] [Related]
15. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
[TBL] [Abstract][Full Text] [Related]
16. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
[TBL] [Abstract][Full Text] [Related]
17. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells.
Yeh JY; Huang WJ; Kan SF; Wang PS
Prostate; 2003 Feb; 54(2):112-24. PubMed ID: 12497584
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells.
Rimler A; Lupowitz Z; Zisapel N
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():45-9. PubMed ID: 12019351
[TBL] [Abstract][Full Text] [Related]
20. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.
Seth D; Shaw K; Jazayeri J; Leedman PJ
Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
